Table 6. Oligoprogressive disease comparison summary.
| Author | Disease site | PFS (months) | OS (months) | LC (12 months) | Number of oligoprogressive cases |
|---|---|---|---|---|---|
| Current study | NSCLC | 8 | 30 | 77.9% | 15 |
| Weickhardt et al., 2012 (29) | NSCLC | 6.2 | NA | NA | 25 |
| Gan et al., 2014 (30) | NSCLC | 5.5 | 39 | 86% | 14 |
| Chan et al., 2017 (31) | NSCLC | 7 | 28.2 | NA | 24 |
| Merino Lara et al., 2018 (32) | NSCLC | 7.6 | 39.3 | 84.4% | 20 |
| Jiang et al., 2019 (33) | NSCLC | 13.9 | 28.3 | NA | 24 |
| Borghetti et al., 2019 (34) | NSCLC | NA | 23 | NA | 49 |
| Santarpia et al., 2020 (35) | NSCLC | 6.3 | 38.7 | NA | 36 |
| Kagawa et al., 2020 (36) | NSCLC | 7.37 | NA | NA | 10 |
| Buglione et al., 2020 (37) | NSCLC | 10.6 | 29.6 | 90% | 198 |
| Wang et al., 2021 (28) | NSCLC | 11 | 51 | 100% | 24 |
| Mahmood et al., 2022 (38) | NSCLC | 6.41 | 29.8 | NA | 59 |
| Xu et al., 2021 (6) | NSCLC | 15 | 26.4 | NA | 38 |
PFS, progression-free survival; OS, overall survival; LC, local control; NSCLC, non-small cell lung cancer; NA, not available.